Cellectar Biosciences, Inc. CLRB
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-63.05
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$21.8M | — | -$23.1M | $8.5M |
| 2024 | — | -$44.6M | — | -$47.7M | $14.3M |
| 2023 | — | -$42.8M | — | -$33.2M | -$15.2M |
| 2022 | — | -$28.6M | — | -$25.4M | $8.2M |
| 2021 | — | -$24.1M | — | -$22.7M | $33.0M |
| 2020 | — | -$15.1M | — | -$14.0M | $54.8M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -63.05 (distress)
- Working capital / assets 0.62
- Retained earnings / assets -17.968
- EBIT / assets -1.534
- Equity / liabilities 1.687
Source: SEC EDGAR filings · CIK 0001279704 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.